SCHEMBL3550310

SCHEMBL3550310

c1cc(CN2CCC[N]CC2)co1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 3/20 0.45
POLB P06746 1/20 0.45
HPGD P15428 1/20 0.45
HRH3 Q9Y5N1 3/20 0.40
LTA4H P09960 1/20 0.40
ROCK2 O75116 1/20 0.38
ROCK1 Q13464 1/20 0.38
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
HRH4 Q9H3N8 1/20 0.37
PARP2 Q9UGN5 1/20 0.37
CYBB P04839 2/20 0.36
NOX5 Q96PH1 2/20 0.36
NOX4 Q9NPH5 2/20 0.36
NOX1 Q9Y5S8 2/20 0.36
PRMT6 Q96LA8 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNA4 P43681 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL42218 0.76 SIGMAR1 (0.61) ALDH1A1POLBHRH3PRMT6CHRNB2
SCHEMBL2088672 0.75 ALDH1A1 (0.67) ALDH1A1KDM4EPOLBHRH3CHRM1
SCHEMBL4828212 0.74 KDM4E (0.50) ALDH1A1KDM4EPOLBHPGDHRH3
SCHEMBL2092380 0.73 ALDH1A1 (0.56) ALDH1A1KDM4EPOLBHRH3HRH4
SCHEMBL2095383 0.73 ALDH1A1 (0.54) ALDH1A1KDM4EHRH3HRH4CXCR4
SCHEMBL2088589 0.73 HRH3 (0.52) ALDH1A1KDM4EHRH3HRH4CXCR4
SCHEMBL2094575 0.73 HRH3 (0.52) ALDH1A1KDM4EHRH3HRH4CXCR4
SCHEMBL16026416 0.73 ALDH1A1 (0.56) ALDH1A1KDM4EPOLBHPGDPARP2
SCHEMBL9050216 0.73 SIGMAR1 (0.56) ALDH1A1KDM4EPOLBHPGDHRH3
SCHEMBL12359436 0.73 MC4R (0.56) ALDH1A1KDM4EPOLBHPGDPRMT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834015-B2 treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV skin damage, and as chemosensitizers or radiosensitizers for cancer treatment INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2010-11-16 US disclosed
US-20090209523-A1 Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209523-A1 Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) PARP1, PARP2, PARP11 ALDH1A1 139/4885KDM4E 3630/4885POLB 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.